Candidate genetic variants included in a genetic risk algorithm may not meet standards of reasonable clinical efficacy in identifying opioid use disorder risk, according to a study published in JAMA ...

One participant in the drug trial for Journavx said it eliminated her pain without making her feel loopy or nauseous, which ...

Every year, thousands of people die from overdosing on opioids in the United States. But a new non-opioid pain medication, ...

The U.S. Food and Drug Administration has approved Journavx (suzetrigine) 50 milligram oral tablets, a first-in-class non-opioid analgesic, to treat moderate to severe acute pain in adults. Journavx ...

The Food and Drug Administration (FDA) is hoping a newly approved non-opioid pain medication could help save lives. Dr.

The opioid epidemic continues to affect hundreds of thousands of people, but there may be hope for the future with a new, non ...

Rutgers Health, in partnership with the New Jersey Department of Labor and Workforce Development (NJDOL), has launched the ...

Introducing Journavx: the FDA-approved non-opioid, non-addictive drug for acute pain. A major breakthrough in pain medication ...

Federal officials approved a new type of pain drug designed to eliminate the risks of addiction and overdose associated with opioid​ medications like Vicodin and OxyContin.

The Phase IIa results continue a surge of momentum in a treatment space that last week saw the approval of Vertex’s Journavx ...

The Food and Drug Administration Jan. 30 announced it approved Journavx (suzetrigine) oral tablets, a first-in-class ...

Patients seeking an opioid-free way to handle pain experienced in the short-term will soon have a new option.